- 专利标题： Indazole and azaindazole Btk inhibitors
-
申请号： US15564352申请日： 2016-04-04
-
公开(公告)号： US10246457B2公开(公告)日： 2019-04-02
- 发明人: Tony Siu , Michael D. Altman , Brian M. Andresen , Jian Liu , Joseph Kozlowski , Sobhana Babu Boga , Younong Yu , Rajan Anand , Jiaqiang Cai , Dahai Wang , Shilan Liu
- 申请人： MERCK SHARP & DOHME CORP.
- 申请人地址： US NJ Rahway
- 专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人： Merck Sharp & Dohme Corp.
- 当前专利权人地址： US NJ Rahway
- 代理商 Matthew A. Leff; Laura M. Ginkel
- 优先权： WOPCT/CN2015/076041 20150408
- 国际申请： PCT/US2016/025809 WO 20160404
- 国际公布： WO2016/164285 WO 20161013
- 主分类号： C07D471/04
- IPC分类号： C07D471/04 ; C07D401/14 ; C07D405/14 ; C07D401/10 ; C07D403/04 ; C07D403/10 ; C07D403/14 ; C07D409/14 ; A61P19/02 ; A61K45/06 ; C07D231/56 ; C07D413/14
摘要：
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, wherein X1, X2, R1, R7, R8 and R9 are as herein described. The present invention also provides pharmaceutical compositions comprising these compounds and methods for their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
公开/授权文献
- US20180127411A1 INDAZOLE AND AZAINDAZOLE BTK INHIBITORS 公开/授权日：2018-05-10
信息查询
